This study focuses on adults with immune thrombocytopenia (ITP), a condition where the immune system mistakenly attacks and destroys blood platelets, leading to increased risk of bleeding. The research evaluates a combination treatment using two medications: rituximab and belimumab.
The purpose of this research is to determine if combining rituximab with weekly injections of belimumab works better than rituximab with placebo in treating persistent or chronic immune thrombocytopenia. The study will last for 104 weeks (2 years), during which patients will receive either belimumab or placebo injections for 24 weeks, along with two doses of rituximab given early in the treatment period.
Throughout the study, researchers will monitor platelet levels, immune system components, and overall health status. The treatment involves subcutaneous (under the skin) injections of belimumab or placebo, while rituximab is given through intravenous administration. Patients will have regular check-ups to monitor their response to treatment and any potential side effects.
France 
